Q2 2023 EPS Estimates for Gamida Cell Ltd. (NASDAQ:GMDA) Raised by Analyst

Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) – Investment analysts at HC Wainwright raised their Q2 2023 earnings estimates for Gamida Cell in a research report issued to clients and investors on Monday, May 22nd. HC Wainwright analyst V. Bernardino now expects that the company will earn ($0.17) per share for the quarter, up from their prior estimate of ($0.21). HC Wainwright currently has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Gamida Cell’s current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Gamida Cell’s Q3 2023 earnings at ($0.14) EPS, Q4 2023 earnings at ($0.08) EPS, FY2023 earnings at ($0.63) EPS and FY2024 earnings at ($0.26) EPS.

A number of other analysts have also recently weighed in on the stock. Oppenheimer dropped their price objective on shares of Gamida Cell from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Monday, March 27th. Needham & Company LLC dropped their price objective on shares of Gamida Cell from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, April 20th. Finally, JMP Securities dropped their price objective on shares of Gamida Cell from $8.00 to $6.00 in a report on Friday, May 19th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $7.60.

Gamida Cell Stock Down 3.9 %

GMDA stock opened at $1.98 on Wednesday. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 5.31. Gamida Cell has a fifty-two week low of $0.56 and a fifty-two week high of $3.66. The firm’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $1.48. The stock has a market cap of $147.27 million, a PE ratio of -3.41 and a beta of 1.62.

Hedge Funds Weigh In On Gamida Cell

Several large investors have recently bought and sold shares of GMDA. JPMorgan Chase & Co. increased its stake in Gamida Cell by 12.8% during the 1st quarter. JPMorgan Chase & Co. now owns 731,328 shares of the company’s stock valued at $3,035,000 after buying an additional 83,009 shares during the period. Federated Hermes Inc. boosted its position in shares of Gamida Cell by 17.5% during the 1st quarter. Federated Hermes Inc. now owns 5,128,300 shares of the company’s stock valued at $21,282,000 after purchasing an additional 764,985 shares in the last quarter. Mariner LLC boosted its position in shares of Gamida Cell by 8.3% during the 1st quarter. Mariner LLC now owns 621,334 shares of the company’s stock valued at $2,579,000 after purchasing an additional 47,587 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Gamida Cell by 539.0% during the 1st quarter. Bank of America Corp DE now owns 15,214 shares of the company’s stock valued at $63,000 after purchasing an additional 12,833 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Gamida Cell by 0.9% during the 2nd quarter. FMR LLC now owns 4,630,125 shares of the company’s stock valued at $8,195,000 after purchasing an additional 42,421 shares in the last quarter. Institutional investors and hedge funds own 56.19% of the company’s stock.

About Gamida Cell

(Get Rating)

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies.